Canadian Nuclear Laboratories’ (CNL) Canadian Nuclear Research Initiative-Health Program (CNRI-H) is a program developed by CNL to further the realization of its mission by making its expertise, experience and capabilities available and accessible to the healthcare community to advance new life saving radiopharmaceutical therapies. The focus of the program is Radiopharmaceutical Discovery, Toxicology and Pre-clinical Evaluation research, and the goal of the program is to accelerate the discovery, development and approval of targeted radiopharmaceuticals for the benefit of Canadians while increasing the safety and efficacy of therapies that involve radiopharmaceuticals.
Canadian Nuclear Research Initiative: Health (CNRI-H)
CNL will be working with the selected third party proponents in Canada and internationally on projects delivered as contract research. CNL would be part-funding these projects by contributing significantly to the project cost as a matching grant in-kind (see CNRI-H: Program Guidelines document below for more details).
Annually, CNL will issue CNRI-H call for proposals (CFP), review the proposals received and select the proposals that fall within defined preselection criteria. CNL will then proceed to enter into a contractual relationship with the selected party to deliver the project. CNL does not intend to share in the ownership of R&D deliverables under the CNRI-H program. Project execution will begin in April 2023 and continue for a maximum of 24 months.
For more information, or to submit your proposal, email commercial@cnl.ca.
CNRI Program Timeline
January 25, 2023 / CNRI-H call for proposals open
March 10, 2023 / Deadline for proposal submission. 12 PM ET
March 31, 2023 / CNL reviews and selects proposals to proceed to negotiations.
June 2023 / Successful agreements announced and work begins.
Focus Areas
A call for proposals (CFP) will be issued as part of the CNRI program. Included in each CFP will be a list of focus areas. The list of focus areas is as follows:
Targeted Radiopharmaceutical Delivery Systems
Toxicology
Pre-Clinical Evaluation
Potential Award Details
CNL will enter into a series of jointly funded R&D projects that will utilize S&T services from CNL to accelerate the discovery, development and approval of targeted radiopharmaceuticals for the benefit of Canadians. Projects must be within the CNRI program focus areas. Applicants are expected to, at a minimum, match the value contributed by CNL in monetary or in-kind contribution.
